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Abstract
One of the most feared consequences of cancer is the possibility of severe and uncon-
trolled pain in patients with advanced cancer. Patients with head and neck cancer (HNC) 
have the highest prevalence of pain among patients with cancer, and it is often one of 
the major reasons for seeking care. A subspecialty approach that incorporates anatomi-
cal and technical knowledge to alleviate pain through minimally invasive procedures is 
relatively recent. The purpose of this chapter is to present different interventional tech-
niques which are used for the treatment of pain in HNC patients when drug treatment 
is unsuccessful.
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1. Introduction 
Interventional procedures in the treatment of head and neck cancer (HNC) pain have been 
proposed in the past 25 years due to the greater knowledge of the mechanisms of action of pain 
and its physiological and anatomical basis. There has been development of new techniques to 
treat refractory pain and treatment strategies with an integral view of the problem. In addi-
tion to the progress of knowledge and development of techniques and technologies, educa-
tion and pain medicine certification programs have been developed around the world [1].
Pain and symptoms associated with HNC is a challenge due to the rich innervation and loss 
of function caused by tumor invasion or by the treatment of cancer [2].
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Pain is the first symptom in 20–50% of patients with cancer; however, in patients with HNC, it 
can become as high as 85%. Of this, 93% are mixed (nociceptive and neuropathic) and 30% are 
neuropathic pain due to tumor involving tissues or metastatic disease. In up to 85% of patients, 
pain is the main cause of medical attention [3]. Compared to other types of cancer, the highest 
incidence of pain in patients with HNC is due to the intense innervation of anatomical structures.
Common neuropathic syndromes associated with cancer are chemotherapy-induced neu-
ropathy, tumor invasion (leptomeningeal metastases), neuralgias (trigeminal neuralgia or 
postherpetic neuropathy, glossopharyngeal neuralgia), radiculopathies and plexopathies, 
paraneoplastic sensory neuropathies, Horner’s syndrome, postsurgery neuropathies, and 
postradiotherapy neuropathies [4, 5].
HNC is generally a disfiguring disease. In addition, it impairs the quality of life (QOL) of 
patients because it interferes with speech, swallowing, and chewing, the key factors in the 
patient’s autonomy [6].
Not all HNC patients who have pain are due to cancer. Sometimes, it occurs due to medi-
cal or surgical treatment. Some studies report cancer-related pain in 52% of the hospitalized 
patients, of which 50% was due to surgery and 29% directly related to the tumor [7].
One of the adverse effects associated with HNC treatment is orofacial pain. Oral mucositis is 
the most frequent complaint impairing the QOL of the patient. This is mediated by elevated 
inflammatory factors, which play a central role in the activation of cytokines, such as TNF-α, 
that is known to be involved in mediation of neuropathic pain and hyperalgesia. Combined 
chemotherapy and radiation therapy results in increased frequency, severity and duration of 
mucositis. The treatment given to patients with HNC represents an important impact on the 
development of pain and the magnitude of it [7, 2].
Radiotherapy is another important cause of pain in HNC, because it creates a hypoxic envi-
ronment, and hypoxic nerves are more vulnerable to neuropathic pain. In long term, chronic 
hypoxia leads to fibrosis in perineural tissues and causes late onset neuropathic pain, even in 
cancer-free survivors [7, 2].
Approximately 50% of HNC patients report orofacial pain before radiation therapy, 81% during, 
and 70% at the completion of treatment. Thirty-six percent of HNC patients report pain after 
6 months of treatment, and 30% experience pain beyond 6 months. The severity of pain varies 
among different disease sites and over the treatment course [8]. Pain intensity usually stays the 
highest during disease treatment (surgery, chemotherapy, radiotherapy) and may take 6 months 
or more to reach initial levels (pre-treatment).
2. Factors associated with head and neck cancer pain
2.1. Age and gender
Age is an important factor in pain perception, according to studies comparing age groups. 
The group of patients who reported pain was younger than 65 years. A higher pain scale 
among females were reported compared to males, however, significantly higher levels of pain 
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among males compared to female was reported also. There are some other factors associated 
with pain such as improper oral hygiene, depression, and anxiety. The presence of metallic 
taste was seen as a predictor of spontaneous pain.
2.2. Cancer-related factors
Patients with tumors in the oral cavity have a lower QOL, as well as worse pain, compared to 
other sites. Patients with end-stage tumors report greater pain compared to stages I and II, as 
well as an increase in spontaneous pain in patients with nodal disease [8].
3. Interventional management for HNC patients
Trigeminal (CNV) and facial (CNVII) nerves are by far the most frequently affected cranial 
nerves, alone or in combination. The predilection for these two specific nerves is explained 
by their wide anatomic distribution in the craniofacial territory and their rich anastomotic 
connections.
The supply of opioid drugs is insufficient in some countries, or not all the population has 
access to it; for this reason, it is necessary to have an interventional tool to manage cancer 
pain. There is a good evidence for the “early integration” of interventional pain treatments 
for carefully selected head and neck cancer patients, at the same time or even before starting 
strong opioids.
4. Sphenopalatine ganglion (SPG) block
SPG is located within a triangular structure with a superior base called pterygopalatine fossa, 
which has a close relationship with the maxillary nerve and very close to the sphenopalatine 
foramen [9]. It is a complex neural center with multiple connections to trigeminal, facial, and 
sympathetic systems and consists of somatosensory, sympathetic, and parasympathetic fibers.
The ganglion is located just below the maxillary nerve and receives three nerve roots: The 
sensory root of the sphenopalatine branches from the maxillary nerve, the motor root from 
the intermediate nerve (part of the facial nerve) through the major petrosal nerve, and the 
sympathetic root from the internal carotid plexus.
In 1908, Sluder proposed an inflammatory reaction in the territory of pterygopalatine fossa 
that may be involved in certain cases of unilateral facial pain associated with rhinorrhea, 
lacrimation and mucosal congestion. Ruskin later described the blocking technique with local 
anesthetic to treat a variety of conditions associated with headache [10].
4.1. Indications for SPG block
Some of the indications for the SPG block are trigeminal neuralgia, persistent idiopathic facial 
pain (previously referred to as atypical facial pain), acute migraine, acute and chronic cluster 
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headache, SP neuralgia, herpes zoster involving the head, and a variety of other facial neural-
gias, including tumor invasion.
Sphenopalatine ganglion neuralgia consists mainly of neuropathic symptoms, but is accom-
panied by sensory, motor, and gustatory manifestations. It is common for the symptoms to be 
episodes of vasomotor hyperactivity such as lacrimation, discharge and inflammation of the 
nasal mucosa, and alteration of gustatory sensation of the palate and oropharynx.
The procedure consists of accessing the pterygopalatine fossa by placing local anesthetic 
with or without steroids, radiofrequency ablation, or pulsed radiofrequency. It may be 
used for diagnosis or treatment of the conditions described above. It is mandatory that 
these procedures are performed under radiographic imaging. It is essential that the ptery-
gopalatine fossa is clearly visualized and confirmed before starting the procedure [11]. 
(See Figure 1).
Figure 1. Sphenopalatine ganglion block.
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5. Trigeminal ganglion block (Gasserian ganglion)
The trigeminal nerve is the most developed and extensive cranial nerve with a large territory 
of distribution. This nerve consists of sensitive fibers (touch, pain, temperature) and motor of 
the face (chewing). It originates in the posterior fossa and lies in the Meckel’s cavity (medial 
cranial fossa), from which originate their three terminal branches: ophthalmic nerve (V1), 
maxillary (V2), and mandibular nerve (V3).
There are several causes of secondary trigeminal neuralgia, which are tumors compressing 
the trigeminal nerve, vascular compressions in close relation with the nerve, or tumors in 
cerebellopontine angle.
The typical clinical presentation of trigeminal neuralgia is sudden, unilateral electrical shock-
like pain dispersed among pain-free intervals along the side of the face. Paroxysmal attacks 
are frequently triggered by chewing, brushing teeth, laughing, talking, and even smiling. It 
is often referred to as the most excruciating pain syndrome known today affecting quality 
of life. In contrast, clinical criteria of atypical facial pain consist of persistent facial pain that 
does not have the characteristics of cranial neuralgias and cannot be attributed to a different 
disorder [12].
Figure 2. Gasserian ganglion block.
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An approach is with fluoroscopy in oblique submental view. In this technique, foramen ovale 
is visualized; usually medially to the mandibular process, and then the needle is advanced 
toward the foramen, first in submental view and then in the lateral view to control depth.
One technique used to selectively injure the branches of the trigeminal nerve is continuous 
radiofrequency. This method allows identifying the affected branch by sensory and motor 
stimulation with conscious sedation. It is a percutaneous technique using the approach 
described by Hartel through the foramen ovale. An electrode is introduced through the nee-
dle (with an active tip of 2–5 mm) to make the lesion (ranges from 60–90°C). The deliberately 
damaged nerve is then no longer able to transmit nociceptive signals.
The potential risks of trigeminal rhizotomy include, but are not limited to, facial numbness 
spreading beyond the required area [causing corneal anesthesia (6%) with its risk of ulceration], 
weakness of chewing (4%), and a rare chance of neuropathic pain (1%, anesthesia dolorosa) [13].
There is extensive evidence of the use of continuous radiofrequency for the treatment of tri-
geminal neuralgia, indicated acute pain relief in 97.6% of patients and continued complete 
pain relief at 5-year follow-up in 57.7% of patients. The effectiveness of pulsed radiofrequency 
(PRF) for trigeminal neuralgia is still under debate [13]. (See Figure 2)
6. Glossopharyngeal nerve block
The glossopharyngeal nerve (GPN) is an important consideration as a pain generator or mod-
ulator in cases of pain of the face and neck. Although uncommon as an etiology of head and 
neck pain (0.57–1.3% of cases of facial pain), tumor invasion can lead to glossopharyngeal 
neuralgia, like cerebellopontine angle tumors [14].
Glossopharyngeal neuralgia is characterized by unilateral paroxysmal pain in the oropharynx, 
nasopharynx, larynx, base of the tongue, tonsillar region, and lower jaw and can also radiate 
to the ipsilateral ear. These attacks are excruciatingly painful and typically described as sharp, 
stabbing, “shocks of electricity” the attacks usually last for seconds to 2 minutes. It is charac-
teristic that there are triggers such as chewing, yawning, or stimulation in the oral mucosa [15].
6.1. Indications for GPN block
GPN block is beneficial in alleviating pain due to orofacial cancer. It is used for the treatment 
of glossopharyngeal neuralgia refractory to medical management and for those who are not 
surgical candidates. Diagnostic GPN block should be considered first to predict the response 
to radiofrequency or neurolysis in intractable glossopharyngeal neuralgia and cancer-related 
pain syndromes.
6.1.1. Technique
The patient is placed supine with the head rotated slightly opposite from the affected side. 
The styloid process is used to identify the course of the GPN, just equidistant to mastoid 
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process and angle of the mandible. Once the styloid apophysis is visualized, the needle is 
contacted and carefully redirected posteriorly and the contrast medium is injected under con-
tinuous “live” fluoroscopy.
Complications are secondary to the close proximity to the internal carotid artery (ICA) and inter-
nal jugular vein (IJV) as well as the vagus, accessory, and hypoglossal nerves at the styloid process.
Accidental puncture of the ICA or the IJV can lead to vessel trauma and hematoma forma-
tion. Dysphagia can result from blockade of the glossopharyngeal nerve that provides motor 
innervations to the stylopharyngeus muscle. Blockade of the spinal accessory and hypoglos-
sal nerves can result in temporary weakness of the trapezius muscle and the tongue, respec-
tively. Inadvertent intravascular injection may lead to seizures or cardiovascular collapse. 
Blockade of the vagus nerve can lead to bradycardia, asystole, reflex tachycardia, and syncope 
as well as dysphonia secondary to vocal cord paralysis [15].
7. Stellate ganglion block
There are three cervical sympathetic chains: upper cervical ganglion, middle cervical gan-
glion, and lower cervical ganglion. These ganglions are all connected together. The stellate 
ganglion is composed of the fusion of the inferior cervical chain and the first thoracic gan-
glion, this happens in the 80% of the people; in the rest, the first thoracic ganglion is called 
stellate ganglion [16]. It is located above the muscle longus colli, and this in turn is in the 
anterolateral aspect of the C6 vertebra.
7.1. Indications for stallate ganglion block
Complex regional pain syndrome (CRPS) I and II, vascular insufficiency—Raynaud’s syn-
drome, vasospasm, vascular disease, postherpetic neuralgia and acute herpes zoster, phan-
tom pain, postmastectomy pain, quinine poisoning, hyperhidrosis of upper extremity, cardiac 
arrhythmias, angina, vascular headaches, neuropathic pain syndromes, including central 
pain, cancer pain (neuropathic pain syndromes in cancer pain), atypical facial pain, and tri-
geminal neuralgia.
7.2. Ultrasound technique
There are many techniques described for stellate ganglion block. We will describe the ultra-
sound guided block, because this technique allows us to directly visualize the vascular struc-
tures, thyroid tissue, vertebral artery, pleura, esophagus, and nerve structures, which are 
important for the success of the procedure and avoiding catastrophic complications.
Ultrasound-guided C6 stellate ganglion block (C6-SGB) was first described by Kapral et al. 





. Ultrasound-guided lateral approach increases the efficacy of SGB by deposition of drug 
subfascially with real-time imaging.
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A high-frequency linear ultrasound transducer is placed over the medial border of the ster-
nocleidomastoid muscle in the transverse position at the level of the cricoid notch (approxi-
mately the C6 level). The tip of the needle is placed in the facial plane where the sympathetic 
chain runs, deep to the prevertebral fascia contributing the posterior fascial layer of the carotid 
sheath, and superficial to the fascia investing the longus colli muscle. Using ultrasound guid-
ance, the needle can be placed closer to the target in the correct fascial plane, which will mini-
mize the amount of local anesthetic needed and thus improve patient safety [16].
The ultrasound images at this level should reveal the C6 vertebral body with the Chassaignac 
or the carotid tubercle, the C6 nerve root, the carotid artery, the longus colli muscle, and the 
short posterior tubercle. If the carotid artery blocks access to the cervical sympathetic chain, 
the ultrasound transducer can be slowly moved laterally to help delineate a more lateral nee-
dle trajectory to avoid the carotid artery.
Complications: Bleeding/hematoma, pneumothorax, hemothorax, vertebral artery injury or 
inadvertent injection, inadvertent injection into neuraxis, esophageal trauma, tracheal trauma, 
phrenic nerve injury, brachial plexus injury, recurrent laryngeal nerve injury, and postsympa-
thectomy syndrome.
8. Vertebroplasty for cancer-related cervical vertebral compression 
fractures
Percutaneous vertebroplasty (PVP) was initially described by Galibert et al. [18] as a treat-
ment for vertebral hemagioma. Later, it was gaining popularity for the treatment of pain of 
vertebral origin as metastasis or fractures by compression.
The most common targets of spinal metastasis are thoracic vertebrae (60–80%), followed by lum-
bar (20%) and cervical spine (10%). Although cervical metastases are less prevalent than thoracic 
and lumbar spine, PVP procedure in cervical vertebrae remains technical challenging, because 
of the anatomical structures of the neck. The approach can result in serious complications [19].
PVP was recently suggested as an alternative treatment for spinal metastatic patients who 
were intolerable to surgery and radiotherapy. It is now a well-established procedure com-
prising a percutaneous injection of a biomaterial, usually polymethyl methacrylate (PMMA), 
into vertebral body. In most cases, this procedure significantly relieves pain and stabilizes the 
vertebral body. A significant decrease in visual analogue scale (VAS) and QOL was reported 
in late-stage cancer patients with multiple cervical spinal metastases, with PVP. The grade of 
evidence for the treatment of vertebral fractures associated with metastatic disease is 2B + [3].
9. Intrathecal drug delivery systems (IDDS)
The use of intrathecal therapy [IT] to treat patients with cancer pain has increased since its 
inception in the 1980s. By positioning a catheter in the cerebral spinal fluid, IT therapy may be 
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advantageous over traditional routes because it reduces systemic exposure to the drug and its 
metabolites as the medication is administered directly to the central nervous system.
To reduce the risk of infection in a long-term intrathecal therapy, it is necessary to implant the 
device subcutaneously. Occasionally, an intrathecal drug delivery test may be performed by 
an external catheter. In this way, the infusion of the permanent device is simulated and the 
dose of the opioid is titrated [20]. This treatment is effective to treat both neuropathic and 
nociceptive pain of oncological and non-oncological origin.
Related to HNC pain, the ideal opioid for intrathecal infusion should be hydrosoluble, with 
the intention of having a greater rostral migration.
There are studies that report improvement in pain, mood, function, as well as, an improve-
ment in depression and anxiety in cancer patients at a follow-up of 36 months among patients 
undergoing intrathecal opioid therapy.
The potential complications of IDDS include opioid-induced hyperalgesia, hypotension, 
sedation, respiratory depression, inflammatory mass “granuloma at the tip of the catheter,” 
Figure 3. Intrathecal therapy.
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hypogonadotropic hypogonadism, and immunologic compromise. The potential for these 
consequences can be diminished with careful dosing and titration. The patient should be 
monitored 24 hours after increasing the dose to decrease the risk of respiratory depression 
and mortality (See Figure 3).
10. Peripheral nerve blocks, cervical epidural, and medial branch block
Occipital neuralgia is a debilitating disorder first described in 1821 as recurrent headaches 
localized in the occipital region. Other symptoms that have been associated with this condi-
tion include paroxysmal burning and aching pain in the distribution of the greater, lesser, or 
third occipital nerves.
10.1. The greater occipital nerve
The HNC-associated headache may be due to entrapment of great occipital nerve (GON), 
third occipital nerve (TON), or irritation of either of them due to tumor invasion [21, 22]. 
There are different structures in the cervical region that can cause head and neck pain, due to 
tumor invasion. The cervicogenic headache is a secondary headache associated with the first 
cervical segments.
Occipital nerve block is an effective therapeutic tool in treating a variety of headache dis-
orders including occipital neuralgia, migraine, cluster headaches and tumor invasion. The 
mechanism of action is a result of blockade of nociceptive afferent fibers supplying the poste-
rior head and upper cervical region (C1–C3) which join trigeminal fibers at the trigeminocer-
vical complex [21, 22].
Occipital nerve block and C2–C3 medial branch can be used to treat cervicogenic headache 
and cancer-related cervical pain, using corticosteroids or radiofrequency. They can be per-
formed percutaneously with an insulated cannula, applying local heat to the sensitive branch 
with the intention of diminishing the sensitivity. Both nerve blocks are easy to perform and 
well tolerated with a few side effects.
11. Botulinum neurotoxin (BoNT)
Botulinum neurotoxin derived from Clostridium botulinum, not only has been used for cos-
metic purposes but also therapeutically for focal dystonia, spasticity, and chronic migraine. 
There is some evidence that it inhibits the release of peripheral neurotransmitters and 
inflammatory mediators from sensory nerves; so, its spectrum as a potential treatment for 
neuropathic pain has grown.
The main mechanism of BoNT is the inhibition of acetylcholine (Ach) release at presynaptic nerve 
terminals, resulting in a reduction of muscle fiber activity, and the innervated structure becomes 
paralyzed [23]. It has also been suggested that BoNT acts by inhibiting neurogenic inflammation 
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by interfering with local release of neurotransmitters, such as calcitonin gene-related peptide, sub-
stance P and glutamate, as well as expression of transient receptor potencial v member 1 (TRPV1).
BoNT is injected into painful areas of the body. Injection techniques primarily include either 
intradermal or subcutaneous injections. It is important to mention that there are different 
reports of BoNT administration in patients with trigeminal neuralgia and other neuralgias in 
the head and face with significant improvement in VAS and QOL.
12. Conclusions
The increasing need for adequate pain control has led us to enter into interventional pain 
management. There is good evidence of early integration of interventional treatments in can-
cer pain [24]. The field of interventional pain management grows very fast throughout the 
world and is a tool that every physician involved in treatment of cancer must value and offer 
to patients for a more comprehensive management of the disease.
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